Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: Shortfall in efficacy or trial design?

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 875-885

  Nathan, Steven D ^a   King, Christopher S ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Interstitial lung disease; Phenotype

Indexed keywords

AMBRISENTAN; BOSENTAN; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; RESPIRATORY TRACT AGENT; SILDENAFIL; TREPROSTINIL; VASODILATOR AGENT;

ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FUNCTION TEST; FUNCTIONAL ASSESSMENT; HOSPITALIZATION; HUMAN; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; MORTALITY; PHENOTYPE; PULMONARY HYPERTENSION; QUALITY OF LIFE; SELF REPORT; SIX MINUTE WALK TEST; STUDY DESIGN; TREATMENT OUTCOME; TREATMENT PLANNING; CLINICAL TRIAL (TOPIC); COMPLICATION; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; METHODOLOGY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; VASODILATOR AGENTS;

EID: 84903882022     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S64907     Document Type: Article

References (57)

1. Nathan SD, Hassoun PM. Pulmonary hypertension due to lung disease and/or hypoxia. Clin Chest Med. 2013; 34(4): 695-705.
2. Simonneau G, Gatzoulis MA, Adatia I, etal. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(Suppl 25): D34-D41.
3. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med. 2007; 175(9): 875-880.
4. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013; 5: 483-492.
5. King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med. 2013; 19(5): 466-473.
6. Panos RJ, Mortenson RL, Niccoli SA, King TE. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990; 88(4): 396-404.
7. Nathan SD, Shlobin OA, Weir N, etal. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011; 140(1): 221-229.
8. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129(3): 746-752.
9. Nadrous HF, Pellikka PA, Krowka MJ, etal. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005; 128(4): 2393-2399.
10. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med. 2009; 103(2): 180-186.
11. Sherner J, Collen J, King CS, Nathan SD. Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. Curr Respir Care Rep. 2012; 1: 233-242.
12. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007; 131(3): 657-663.
13. Zisman DA, Karlamangla AS, Ross DJ, etal. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2007; 132(3): 773-779.
14. Krowka MJ, Ahmad S, de Andrade JA, etal. A Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis [abstract]. Chest. 2007; 132(4 MeetingAbstracts): 633a-633.
15. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010; 363(7): 620-628.
16. Ghofrani HA, Wiedemann R, Rose F, etal. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360(9337): 895-900.
17. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131(3): 897-899.
18. Günther A, Enke B, Markart P, etal. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J. 2007; 29(4): 713-719.
19. Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gómez-Marín O. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung. 2010; 188(2): 115-123.
20. King TE, Behr J, Brown KK, etal. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 177(1): 75-81.
21. Raghu G, Behr J, Brown KK, etal; ARTEMIS-IPF Investigators*. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158(9): 641-649.
22. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J; MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013; 42(6): 1622-1632.
23. Han MK, Bach DS, Hagan PG, etal; IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013; 143(6): 1699-1708.
24. Seeger W, Adir Y, Barberà JA, etal. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62(25 Suppl D): D109-D116.
25. Nathan SD, Shlobin OA, Barnett SD, etal. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2008; 102(9): 1305-1310.
26. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005; 16(1): 13-18.
27. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008; 117(13): 1717-1731.
28. Saggar R, Khanna D, Vaidya A, etal. Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax. 2014; 69(2): 123-129.
29. Hamada K, Nagai S, Tanaka S, etal. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007; 131(3): 650-656.
30. Nathan SD, Shlobin OA, Ahmad S, etal. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008; 76(3): 288-294.
31. Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med. 2008; 34(6): 994-1001.
32. Snow JL, Kawut SM. Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy. Clin Chest Med. 2007; 28(1): 75-viii.
33. Albera C. Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev. 2011; 20(121): 195-200.
34. Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation. 2012; 126(3): 258-260.
35. Gabler NB, French B, Strom BL, etal. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012; 126(3): 349-356.
36. Savarese G, Paolillo S, Costanzo P, etal. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012; 60(13): 1192-1201.
37. Gomberg-Maitland M, Bull TM, Saggar R, etal. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol. 2013; 62(Suppl 25): D82-D91.
38. Dolmage TE, Hill K, Evans RA, Goldstein RS. Has my patient responded? Interpreting clinical measurements such as the 6-minute-walk test. Am J Respir Crit Care Med. 2011; 184(6): 642-646.
39. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1): 111-117.
40. Lama VN, Flaherty KR, Toews GB, etal. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168(9): 1084-1090.
41. Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006; 100(10): 1734-1741.
42. Swigris JJ, Wamboldt FS, Behr J, etal. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010; 65(2): 173-177.
43. Swigris JJ, Swick J, Wamboldt FS, etal. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest. 2009; 136(3): 841-848.
44. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology. 2011; 16(3): 439-445.
45. Weir NA, Brown AW, Shlobin OA, etal. The influence of alternative instruction on 6-min walk test distance. Chest. 2013; 144(6): 1900-1905.
46. Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest. 2012; 142(2): 291-297.
47. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax. 2010; 65(10): 921-926.
48. Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes. 2010; 8: 77.
49. Noth I, Anstrom KJ, Calvert SB, etal; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186(1): 88-95.
50. Pulido T, Adzerikho I, Channick RN, etal; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9): 809-818.
51. Raghu G, Collard HR, Anstrom KJ, etal. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012; 185(10): 1044-1048.
52. Taichman DB, McGoon MD, Harhay MO, etal. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc. 2009; 84(7): 586-592.
53. King TE, Albera C, Bradford WZ, etal. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014; 189(7): 825-831.
54. Kaul S, Diamond GA. Trial and error. How to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol. 2010; 55(5): 415-427.
55. Minai OA, Sahoo D, Chapman JT, Mehta AC. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med. 2008; 102(7): 1015-1020.
56. Raghu G, King TE Jr, Behr J, etal. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J. 2010; 35(1): 118-123.
57. King TE, Brown KK, Raghu G, etal. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184(1): 92-99.